At the same time, there is evidence that has shown that the inhibition of interleukin-1 has led to a decrease in the relative risk of atherothrombotic events and in the development of new cases of lung cancer and can, at least partially, realize its effects through the suppression of CXCL12/CXCR4 signaling [39]. This evidence concerns the gene CXCR4 and lung carcinoma.